Table 1.
Clinical presentations and diagnostic evaluation of patients with PPGL.
| Age at diagnosis, median (range) years | Total (23) | PCC (14) | PGL (9) | |||
|---|---|---|---|---|---|---|
| 16.8 (6.8–20.8) | 17.6 (13.3–20.3) | 13.7 (6.8–20.8) | ||||
| Gender, n (%) | M | F | M | F | M | F |
| 15 (65.2%) | 8 (34.8%) | 10 (71.4%) | 4 (28.6%) | 5 (55.6%) | 4 (44.4%) | |
| Main presenting symptoms | ||||||
| Hypertension Headache Palpitation Sweating Incidental |
10 9 4 4 2 |
7 5 4 3 1 |
3 4 0 1 1 |
|||
| Catecholamine and/or metabolite in plasma or 24-hour | ||||||
| urine, n (%) | ||||||
| Elevated Normal |
22 (95.7%) 1 (4.3%) |
14 (100%) 0 |
8 (88.9%) 1 (11.1%) |
|||
| Imaging performed to diagnose | ||||||
| CT MRI MIBG PET |
22 2 8 9 |
13 0 4 8 |
9 2 4 1 |
|||
| Location of primary tumor, n (%) | Unilateral 9 (64.3%) Bilateral 5 (35.7%) |
Neck 1 (11.1%) Retroperitoneum 8 (88.9%) |
||||
| Metastasis | 3 (13%) | 1 (7.1%) | 2 (22.2%) | |||
| Recurrence | 3 (13%) | 3 (21.4%) | 0 (0%) | |||
PPGL, PCC and PGL; PCC, pheochromocytoma; PGL, paraganglioma; CT, computed tomography; MRI, magnetic resonance imaging; MIBG, meta-iodobenzylguanidine scintigraphy; PET, positron emission tomography; M, male; F, female.